- Home
- LDWY vs NCNA Comparison
LDWY vs NCNA Comparison
Compare LDWY & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- NCNA
- Stock Information
- Founded
- LDWY 1990
- NCNA 1997
- Country
- LDWY United States
- NCNA United Kingdom
- Employees
- LDWY N/A
- NCNA N/A
- Industry
- LDWY Advertising
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- NCNA Health Care
- Exchange
- LDWY Nasdaq
- NCNA Nasdaq
- Market Cap
- LDWY 8.9M
- NCNA 7.6M
- IPO Year
- LDWY 1991
- NCNA 2017
- Fundamental
- Price
- LDWY $4.90
- NCNA $6.88
- Analyst Decision
- LDWY
- NCNA
- Analyst Count
- LDWY 0
- NCNA 0
- Target Price
- LDWY N/A
- NCNA N/A
- AVG Volume (30 Days)
- LDWY 3.0K
- NCNA 768.1K
- Earning Date
- LDWY 11-18-2025
- NCNA 11-24-2025
- Dividend Yield
- LDWY N/A
- NCNA N/A
- EPS Growth
- LDWY N/A
- NCNA N/A
- EPS
- LDWY 1.66
- NCNA N/A
- Revenue
- LDWY $71,244,000.00
- NCNA N/A
- Revenue This Year
- LDWY N/A
- NCNA N/A
- Revenue Next Year
- LDWY N/A
- NCNA N/A
- P/E Ratio
- LDWY $3.02
- NCNA N/A
- Revenue Growth
- LDWY 187.12
- NCNA N/A
- 52 Week Low
- LDWY $3.02
- NCNA $2.78
- 52 Week High
- LDWY $6.19
- NCNA $446.00
- Technical
- Relative Strength Index (RSI)
- LDWY 44.44
- NCNA 74.46
- Support Level
- LDWY $4.57
- NCNA $3.79
- Resistance Level
- LDWY $5.45
- NCNA $5.07
- Average True Range (ATR)
- LDWY 0.19
- NCNA 0.56
- MACD
- LDWY -0.03
- NCNA 0.18
- Stochastic Oscillator
- LDWY 32.04
- NCNA 99.06
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.